• About PAH

•      Indications

•      Clinical Trials

•      Efficacy

•           Clinical Improvement

•           Improved Exercise
            Capacity

•           Functional Class
            Improvement

•           Improved
            Hemodynamics

•      Safety Profile

•      Dosage & Administration

•      Ventavis AirTime

•      FAQs

•      Ventavis Support

• About the I-neb AAD
  System

• Services for Your Patients

• Resources

• Prescribing Information

• For Patients and
  Caregivers

About Ventavis^® (iloprost)

Ventavis is an inhaled synthetic analogue of prostacyclin PGI₂ that produces potent pulmonary vasodilation and inhibits platelet aggregation, among other benefits.^1,2 Ventavis is the only FDA-approved pulmonary arterial hypertension (PAH) medication studied to date that has shown patient improvement as the primary endpoint (improvement in functional class, 10% or greater increase in individual walk distance, and lack of clinical deterioration or death).

Because it is inhaled, Ventavis avoids the complications associated with parenteral prostacyclin therapy which may include serious bloodstream infections, pain associated with subcutaneous prostacyclin delivery, and the potential for pump and catheter-related complications associated with IV and subcutaneous prostacyclin therapies.

In addition, Ventavis offers patients strong support programs—PAH Pathways™ and Sure Steps™—staffed by healthcare professionals who provide information about PAH, and support for obtaining Ventavis therapy. Patients value these support services³ which provide frequent communication, disease education, and daily access to trained nurse counselors.

Take time to read through the remainder of this section to learn more about this unique therapy for your NYHA Functional Class III and IV PAH patients.

Indicated for NYHA Class III or IV patients

• Prostacyclin (PGI₂) functions as a hormone, binding to receptors on smooth muscle cells, thereby affecting their function. Prostacyclin has multiple physiological effects, including vasodilation, inhibition of platelet aggregation, antiproliferation, anti-inflammation, and enhanced cardiac contractility.
• Ventavis is an inhaled synthetic prostacyclin which has been shown to
  • Significantly increase patient improvement (improvement in functional class, 10% or greater increase in individual walk distance, and no clinical deterioration) at week 12 of therapy (p=0.0033)^1,2†
  • Significantly improve 6-minute walk distance at week 12 (p<0.01)^1,2†
  • Significantly improve patients' functional class at week 12 (p=0.03)^1,2
• Both functional class III and class IV patients showed improvement by at least one functional class^1†
• Ventavis gives your patients the benefit of prostacylin therapy and frees them from the necessity of infusion pumps and catheters
  • Avoids the potential for serious bloodstream infections associated with intravenous prostacyclin therapy
  • Avoids site pain and narcotics usage associated with subcutaneous prostacyclin analogues
• No known contraindications¹

† In controlled trials, Ventavis improved a composite clinical endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of clinical deterioration or death. For more information about Ventavis, please see Full Prescribing Information

Read more about Ventavis:

• Indications
• Clinical Trials
• Efficacy
• Clinical Improvement
• Improved Exercise Capacity
• Functional Class Improvement
• Improved Hemodynamics
• Safety Profile
• Dosage & Administration
• Frequently Asked Questions
• Ventavis Support

1. Ventavis (iloprost) Full Prescribing Information. Actelion Pharmaceuticals US, Inc. 2009.
2. Olschewski H, Simonneau G, Galie N et al, for the Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322-329.
3. Harris Poll

For more information about
Ventavis, please call
1-866-ACTELION (1-866-228-3546).